Celcuity Inc. continues to advance its lead asset, gedatolisib, a comprehensive inhibitor of the PAM pathway targeting HR+/HER2- breast cancer and mCRPC in pivotal clinical studies. Recent filings confirm no material change to risk factors but underscore ongoing operational losses and indebtedness that pose financial constraints. The company’s business model hinges on regulatory approvals and successful commercialization of gedatolisib, supported by exclusive licensing from Pfizer and diligent trial execution. Growth drivers include Phase 3 enrollment completion and potential first-line therapy indications, though risks around clinical outcomes, reimbursement, and capital access persist.